Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Taltz (ixekizumab) injection Right
  4. What is the incidence of infections with Taltz® (ixekizumab) in pediatric patients?
Search Taltz (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Taltz ® (ixekizumab) injection

80 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the incidence of infections with Taltz® (ixekizumab) in pediatric patients?

Ixekizumab may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur.

US_cFAQ_IXE317_INFECTIONS_PEDS
US_cFAQ_IXE317_INFECTIONS_PEDS
en-US

Infection-Related Label Information

Ixekizumab may increase the risk of infection. Instruct patients treated with ixekizumab to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue ixekizumab until the infection resolves.1

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ixekizumab. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering ixekizumab. Consider anti-TB therapy prior to initiating ixekizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ixekizumab should be monitored closely for signs and symptoms of active TB during and after treatment.1

In clinical trials of patients with plaque psoriasis, the ixekizumab group had a higher rate of infections than the placebo group (27% vs 23%).

Infections that occurred more frequently in the ixekizumab group than in the placebo group were

  • upper respiratory tract infections
  • oral candidiasis
  • conjunctivitis, and
  • tinea infections.1

Overall, the safety profile observed in pediatric patients with plaque psoriasis treated with ixekizumab Q4W is consistent with the safety profile in adult patients with plaque psoriasis with the exception of

  • conjunctivitis (adults, less than 1%; pediatrics, 2.6%)
  • influenza (adults, less than 1%; pediatrics, 1.7%), and
  • urticaria (adults, less than 1%; pediatrics, 1.7%).1

Treatment-Emergent Infections in IXORA-PEDS

IXORA-PEDS: Treatment-Emergent Infections in the Double-Blind Treatment Period and Combined Treatment Periods Through the 108-Week Final Database Lock provides a summary of treatment-emergent infections reported in ≥3% of ixekizumab-treated patients in IXORA-PEDS. A list of all infections reported in patients receiving ixekizumab in IXORA-PEDS is available in the supplementary material of the Paller et al manuscript.2

During the double-blind treatment period, none of the patients

  • experienced severe or serious infection-related adverse events (AEs)
  • discontinued study drug due to an infection-related AE, and
  • reported opportunistic infections or Candida infections.3,4

In the all ixekizumab exposure population through the 108-week final database lock

  • 2 patients (1.0%) reported serious infections (1 each of otitis media acute and tonsillitis)
  • no patients discontinued study drug due to an infection-related AE
  • one case each of varicella zoster virus infection and herpes simplex virus infection were reported. Both infections were mild, and neither event met the criteria for an opportunistic infection as defined in the program safety analysis plan, and
  • one patient reported a treatment-emergent adverse event of fungal infection, which was a mild oral Candida infection of 5 days duration.2,4,5
IXORA-PEDS: Treatment-Emergent Infectionsa in the Double-Blind Treatment Period and Combined Treatment Periods Through the 108-Week Final Database Lock2-5


12-Week Double-Blind Treatment Period

Combined Treatment Periods, All Ixekizumab Safety Populationb

 

Placebo
(N=56)
n (%)

Ixekizumab Q4W
(N=115)
n (%)

Total Ixekizumab
(N=196)
n (%)

Infections overall

14 (25.0)

37 (32.2)

145 (74.0)

Serious infections

0

0

2 (1.0)c

Opportunistic infections

0

0

0d

Candida

0

0

1 (0.5)e

Nasopharyngitis

4 (7.1)

13 (11.3)

43 (21.9)

Upper respiratory tract infection

4 (7.1)

6 (5.2)

41 (20.9)

Pharyngitis

0

2 (1.7)

22 (11.2)

Tonsillitis

2 (3.6)

1 (0.9)

19 (9.7)

Conjunctivitis

0

3 (2.6)

16 (8.2)

Impetigo

0

1 (0.9)

13 (6.6)

Influenza

0

2 (1.7)

13 (6.6)

Viral upper respiratory tract infection

0

2 (1.7)

13 (6.6)

Pharyngitis streptococcal

0

2 (1.7)

12 (6.1)

Viral infection

2 (3.6)

2 (1.7)

10 (5.1)

Gastroenteritis

0

0

10 (5.1)

Folliculitis

0

1 (0.9)

9 (4.6)

Urinary tract infection

0

0

9 (4.6)

Pharyngotonsillitis

0

1 (0.9)

8 (4.1)

Ear infection

1 (1.8)

1 (0.9)

7 (3.6)

Hordeolum

1 (1.8)

1 (0.9)

7 (3.6)

Oral herpes

0

0

7 (3.6)

Otitis externa

0

2 (1.7)

7 (3.6)

Gastroenteritis viral

0

0

6 (3.1)

Otitis media

0

1 (0.9)

6 (3.1)

Abbreviation: Q4W = every 4 weeks.

aOccurring in ≥3% of ixekizumab-treated patients or adverse event of special interest.

bAll patients exposed to ixekizumab in the induction, maintenance, and extension periods through the 108-week final database lock (342.81 total patient-years of exposure), including patients switched to ixekizumab from placebo or etanercept following the double-blind induction treatment period.

cOne case each of otitis media acute and tonsillitis.

dOne case each of varicella zoster virus infection and herpes simplex virus infection were reported. Both infections were mild, and neither event met the criteria for an opportunistic infection as defined in the program safety analysis plan.

eOne patient (0.5%) reported a TEAE of fungal infection, which was a mild oral Candida infection of 5 days duration. Based on the program safety analysis plan, fungal infection is not a preferred term included in Candida infections and thus is not captured in the Paller et al 2022 publication.

Integrated Safety Across All Ixekizumab Psoriasis Clinical Trials

An integrated safety analysis was conducted from all ixekizumab adult psoriasis exposures (N=6892; 18,025.7 patient-years [PYs]) across 17 adult plaque psoriasis clinical trials as of March 19, 2021. The proportion of patients with

  • any infection was 62.5% [incidence rate (IR)=23.9 per 100 PYs of exposure]
  • serious infection was 3.4% [IR=1.3 per 100 PYs of exposure]
  • all Candida infections was 4.9% [IR=1.9 per 100 PYs of exposure], and 
  • opportunistic infections was 4.6% [IR=1.8 per 100 PYs of exposure].6

The IR of infections did not increase with longer ixekizumab exposure, up to 5 years.7

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2Paller AS, Seyger MMB, Magariños GA, et al; IXORA-PEDS Investigators. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. Published online April 13, 2022. https://dx.doi.org/10.1001/jamadermatol.2022.0655

3Paller AS, Seyger MMB, Magariños GA, et al; IXORA-PEDS Study Group. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231-241. https://doi.org/10.1111/bjd.19147

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

5Paller AS, Seyger MMB, Magariños GA, et al. Long-term efficacy and safety of ixekizumab in a phase 3, randomized, double-blind, placebo-controlled study in pediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) up to 108 weeks. Poster presented at: Annual Meeting of the American Academy of Dermatology (AAD); March 25-29, 2022; Boston, MA.

6Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Poster presented at: Annual Meeting of the American Academy of Dermatology (AAD); March 25-29, 2022; Boston, MA.

7Griffiths CEM, Reich K, Gooderham M, et al. Long-term safety of ixekizumab in patients with moderate-to-severe psoriasis up to 5 years: pooled data from 16 clinical trials. Poster presented at: 29th Annual Meeting of the European Academy of Dermatology and Venereology (EADVirtual); October 29-31, 2020.

Date of Last Review: May 19, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly